Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center by Sirven, Milana Bergamino et al.
RESEARCH ARTICLE Open Access
Real-world efficacy and safety of eribulin in
advanced and pretreated HER2-negative
breast cancer in a Spanish comprehensive
cancer center
Milana Bergamino Sirvén1, Adela Fernández-Ortega1, Agostina Stradella1, Idoia Morilla1, Catalina Falo1,
Silvia Vázquez1, Roser Castany1, Rafael Villanueva1, Sabela Recalde1, Valentí Navarro Pérez2, Miguel Gil-Gil1 and
Sonia Pernas1*
Abstract
Background: Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However,
limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to
review eribulin’s efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI)
and central nervous system (CNS) activity.
Methods: An observational study was conducted in a series of HER2-negative ABC patients treated from
January’14-December’17 outside a clinical trial. Objective Response Rate (ORR), Progression Free Survival (PFS),
Overall Survival (OS), and association of clinical and pathological variables with outcome were evaluated.
Results: Ninety-five women were treated with at least one cycle of eribulin. Median age was 57 (33–83), and 18%
were obese. Median number of prior chemotherapies for ABC was 3 (2–5) and 76% of patients had visceral
metastases, including 21% with CNS involvement. Most tumors were estrogen receptor-positive (79%). ORR and
stable disease (SD) at 6 months were 26.2 and 37.5%, respectively. Remarkably, relevant CNS efficacy was observed
with eribulin: 20% of patients obtained partial response and 25% SD. Treatment was generally well tolerated and
manageable, with 29% grade 3 and 10.9% grade 4 toxicities. Median PFS and OS were 4.1 months (CI95% 3.2–4.9)
and 11.1 months (CI95% 9.5–14.7), respectively. Triple-negative disease, > 2organs involved and being younger than
70 years old were independent prognosis factors for worse OS in multivariate analysis. Most patients (75%)
progressed in pre-existing metastases sites.
Conclusion: In everyday clinical practice, eribulin’s efficacy seems similar to pivotal trials. CNS-efficacy was observed.
TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS.
Remarkably, less incidence of grade 4-toxicity compared to previous studies was found.
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Background
Eribulin mesylate is a synthetic analogue of the marine
halicondrin B, a microtubule-targeting agent approved
for the treatment of metastatic breast cancer. Some pre-
clinical data showed that eribulin can reverse the epithe-
lial–mesenchymal transition (EMT), reducing cancer cell
migration and invasion [1, 2]. Additionally, eribulin has
an antiangiogenic effect and it can cause tumor vascular
remodeling, leading to an increased perfusion into the
tumor and metastases [3–5].
Two phase III randomised studies (EMBRACE and
301 trials) and a pooled analysis of these two studies
showed that eribulin improved overall survival (OS) in
patients with pretreated advanced breast cancer (ABC)
[6–8]. The benefits of eribulin were achieved with a
manageable toxicity profile in both studies. The benefi-
cial effects of eribulin compared with the control were
mainly observed in patients with triple-negative breast
cancer (TNBC) or HER2-negative disease, in patients
with > 2 organs involved and in patients with visceral
disease [8]. Moreover, a reduced incidence of new loca-
tion metastases when patients are treated with eribulin
has been reported in some retrospective studies, prob-
ably due to its biological effect [9–11]. In contrast, few
data exist about prognostic and predictive factors of re-
sponse with eribulin in everyday clinical practice [12, 13]
. Efficacy in elderly patients, obese patients, or in pa-
tients with central nervous system (CNS) disease has not
been well reported either [14–16].
Eribulin was approved in Spain in December 2013 for
patients with HER2-negative recurrent or metastasic breast
cancer previously treated with taxanes, anthracyclines and
capecitabine unless patients were not suitable for those
treatments [17–19]. The purpose of our study was to re-
view eribulin’s activity, in terms of progression-free survival
(PFS) and OS, and tolerability in patients with HER2-
negative ABC treated at ICO-Hospitalet (Barcelona, Spain)
outside of a clinical trial since its approval.
Methods
Study population
An observational study was conducted at ICO-Hospitalet
to review patients with HER2-negative ABC consecutively
treated with single-agent eribulin from January 2014 to
December 2017 in an off-trial setting. All patients in-
cluded may have received at least one cycle of eribulin
1.23mg/m2 day 1 and 8 every 21 days. The treatment was
continued until disease progression, unacceptable toxicity,
or patient withdrawal. Age at diagnosis, body mass index
(BMI), relevant comorbidities, Eastern Cooperative Oncol-
ogy Group (ECOG) Performance Status, tumor subtype,
visceral involvement, pre and post-eribulin chemotherapy
regimens, response rate, clinical benefit, CNS efficacy, tox-
icities and pattern of progression were obtained from
medical records. Toxicity was reported following the
Common Terminology Criteria for Adverse Events
(CTCAE 3.0).
Regarding comorbidity, we did not use the Charlson
Comorbidity Index due to the strong influence of the
presence of metastases (M1) on this scale, but presence
of relevant comorbidity used in that scale was registered
and graded, and we considered it relevant if patients had
one or more comorbidities with grade 2 or higher. In this
study the comorbidity that was considered and graded
was: diabetes mellitus, hypertension, dyslipidemia, myo-
cardial disease such as myocardial infarction and congest-
ive heart failure, chronic pulmonary disease, liver and
renal disease.
Statistical analysis
The characteristics of patients were described and the
Kaplan–Meier method was used to calculate the PFS
and OS as the time-to-event for each endpoint from the
start date of treatment with eribulin to the occurrence
date of the event, progression or death, respectively. An
evaluation of the response was performed by the re-
sponse evaluation criteria in solid tumors (RECIST 1.1.).
Objective response rate (ORR) included complete re-
sponse (CR) and partial response (PR) at the first evalu-
ation (generally performed every 9–12 weeks or if
clinically indicated). Clinical benefit rate included CR,
PR or stable disease (SD) of at least 6 months’ duration.
Statistical differences were estimated using the log-
rank test. The univariate and multivariate analyses were
conducted using the Cox proportional hazard regression
model for PFS and OS to assess the prognostic value of
patients, tumors and treatment characteristics. A two-
tailed p-value of < 0.05 was considered significant. In the
multivariate analysis, we included the variables that
achieved a p-value < 0.1 in the univariate analysis. All
analyses were carried out using the SPSS 22.0 statistical
software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Ninety-five women with HER2-negative ABC were
treated with at least one cycle of eribulin during this
period. Baseline patient and tumor characteristics are
listed in Table 1. Overall, median age was 57 years
(range 33–83), ECOG Performance Status was ≤1 in
88% of patients and only 12.6% of patients had relevant
comorbidities. Median number of organs involved was 3
(range 1–5). Of those patients with CNS involvement
(n = 20), seven (33%) had been previously treated with
whole brain irradiation. In patients pretreated with tax-
anes, 46% progressed during the first 3 months and they
were considered taxane-refractory, based on previous
studies [7].
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Efficacy of eribulin according to patient and tumor
characteristics
Median number of cycles of eribulin received was 7 (1–55).
Dose interruptions, delays and reductions were 14, 26 and
32%, respectively. ORR was 26.2% (all of them PR) and
37.5% of patients had SD, with a clinical benefit observed in
63.7% of patients. Regarding CNS efficacy, 4 patients (20%)
presented a PR, 5 patients (25%) achieved SD and 2 patients
were not evaluated. Remarkably, out of the nine patients
with CNS metastases who progressed during treatment
with eribulin, six (66%) had meningeal carcinomatosis. In
the subgroup of patients without previously known CNS
disease, only two patients progressed to meningeal carcin-
omatosis during treatment with eribulin. Disease control
seemed independent to previous CNS local treatment.
From the seven patients who had been previously treated
with whole brain irradiation, two achieved PR, three SD
and two progressed during treatment with eribulin.
A different pattern of ORR was observed in patients based
on age (< 70 years vs ≥70 years). Clinical benefit was 62% in
the younger group of patients and 51.3% in the older patients,
non-statistically significant (p= 0.299), with 25% vs 31.3%
achieving PR and 37% vs 20% achieving SD, respectively.
At a median follow up of 13months, 16 patients (17%)
were still alive. Median PFS was 4.1months (95% CI 3.2–
4.9) and was significantly shorter in patients with more than
2 organs involved (3.3 vs 5.9months; HR 2; 95% CI 1.22–
3.26, p = 0.01); in patients with TNBC compared to those
with HR-positive tumors (3.3 vs 4.5months; HR 4.16; 95%
CI 3.2–4.9, p = 0.041); in patients with visceral involvement
(3.8 vs 6.2months; HR 5.35; 95% CI 3.2–4.9, p = 0.021); and
in patients < 70 years of age (3.8 vs 6.3months; HR 1.82;
95% CI 1.02–3.25, p = 0.011). Median OS was 11.1months
(95% CI 9.5–14.67) and, similar to what was observed with
PFS, OS was significantly shorter in patients with TNBC
compared to those with HR-positive tumors (5.5 vs 12.4
months; HR 3.36; 95% CI 1.15–4.85, p = 0.049) (Fig. 1a); in
patients with more than 2 organs involved (8.4 vs 16.4
months; HR 3.88; 95% CI 1.95–7.7, p < 0.01) (Fig. 1b); in
patients with visceral involvement (9.2 vs 16.4months; HR
2.33; 95%CI 1.27–4.2, p = 0.005) (Fig. 1c); and in patients <
70 years of age (9.5 vs 27.8months; HR 2.202; 95% CI
1.08–4.4, p = 0.024) (Fig. 1d). Median OS was worse for
taxane-refractory patients (7 vs 12.4months; HR 1.5; 95%
CI 0.406–1.041, p = 0.070) and better for patients who ex-
perienced grade 3 or 4 toxicities (13 vs 9.5 months; HR
1.5; 95% CI 0.916–2.6, p = 0.066), but these differences
were not statistically significant. No differences in PFS or
OS were observed based on comorbidity or weight.
In the multivariate analysis, only TNBC (HR 2.33; 95% CI
1.25–448, p = 0.011), > 2 organs involved (HR 2.27; 95% CI
1.18–4.27, p = 0.009) and < 70 years of age (HR 2.35; 95%
CI 1.07–5.18, p = 0.033) were independent prognostic fac-
tors for worse OS (Table 2).
Table 1 Baseline characteristics of the patients included in the
study (n = 95)
Variable N %
Age
< 70 years old 79 (83%)




Diabetes Mellitus 3 (3.2%)
Cardiorespiratory disease 9 (9.5%)
Liver and renal disease 5 (5.3%)
Relevant comorbidity (≥ grade 2) 12 (12.6%)
BMI
BMI < 25 43 (45%)
BMI 25–30 35 (37%)
BMI > 30 17 (18%)
Histology
Infiltrating ductal carcinoma 84 (88%)
Infiltrating lobular carcinoma 11 (12%)
Tumor subtype
ER and/or PgR positive 75 (79%)

















Number of organs involved
≤ 2 organs 35 (37%)
> 2 organs 60 (63%)
Abbreviations: BMI body mass index, ER estrogen receptor, PgR
progesterone receptor
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Toxicity
Toxicities are listed in Table 3. Twenty-nine percent of
patients suffered grade 3 adverse events (AE) and 10.9%
a grade 4 AE (all neutropenia). The most frequent grade
3 and 4 AEs were asthenia, neurotoxicity and neutro-
penia and were mainly manageable. All grade 3 and 4
toxicities were independent of a patient’s baseline char-
acteristics (age, obesity, tumor subtype, visceral involve-
ment or number of previous chemotherapy regimens).
One patient with grade 4 febrile neutropenia with a skin
infection died due to septic shock.
Pattern of progression
Most patients (n = 72; 75%) progressed in pre-existing
sites of metastases and only 19 (20%) patients experienced
Fig. 1 Kaplan Meier curves for overall survival. a KM curves for TNBC compared to HR-positive tumors. Median OS was significantly shorter in patients
with TNBC compared to ER-positive tumors. b KM for OS for burden of disease (< 2 organs involved compared to > 2 organs involved). mOS was
significantly shorter in patients with more than 2 organs involved compared to those with 2 or less M1. c KM for OS for patients with visceral
involvement compared to non-visceral involvement. mOS was significantly shorter in patients with visceral involvement compared to those without
visceral M1. d KM curves for OS for patients younger than 70 years of age compared to older than 70 years of age. mOS was significantly shorter in
patients younger than 70 years of age compared to those older. Abbreviations: KM: Kaplan Meier; OS: overall survival; TNBC: triple-negative breast
cancer; m: months; ER: estrogen receptor; mOS: median overall survival; CI: confidence interval; M1: metastases; HR: hazard ratio; m: months
Table 2 Multivariate analysis for OS and basal patient and
disease characteristics
HR 95% CI for HR P
valueInferior Superior
Triple negative 2.334 1.215 4.481 0.011
> 2 organs involvement 2.272 1.19 4.274 0.013
Age (< 70 years old) 2.354 1.070 5.180 0.033
Visceral metastases 2.35 0.236 1.259 0.155
Taxane-refractary 0.977 0.566 1.688 0.934
Grade 3–4 toxicities 1.723 0.966 3.072 0.065
Abbreviations: OS overall survival, HR hazard ratio, CI confidence interval
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disease progression in new locations. Four patients out of
those 19 (21%) developed meningeal carcinomatosis. The
remaining 5% of patients had clinical progression without
radiological evidence of disease progression. The main
cause of treatment release was progression (87%) followed
by toxicity (13%). Median number of lines of chemother-
apy received after eribulin was 1 (0–5).
Discussion
In the present analysis of the efficacy of eribulin in an
off-trial setting, PFS and OS in patients with heavily pre-
treated HER2-negative advanced breast cancer were
similar to those observed in the phase III EMBRACE
trial (4.1 vs 3.7 months and 11.1 vs 13.1 months, respect-
ively) [6–8]. Patient characteristics in our study more
closely resemble the patient characteristics in the EM-
BRACE study population than the 301 study population,
as most patients had been previously treated with
anthracyclines, taxanes and capecitabine [6]. In contrast,
the response rate and clinical benefit in our study were
higher than in the EMBRACE trial and more similar to
the 301 trial results [7]. There was an increased risk of
mortality in patients with TNBC compared to HR-
positive disease, given the aggressiveness of this tumor
subtype. In the pooled analyses, longer median OS was
observed in patients with more than two organs involved
and in those with visceral metastases [8]; however, in
our study, more benefit and longer OS were seen in pa-
tients with lower burden of disease and fewer than two
organs involved. The more favourable results obtained
in these subgroups of patients may reflect their inde-
pendent better prognosis [8, 12, 20].
In previous reports, patient age had not been described
as an independent factor for PFS or OS. A pooled
analysis of 827 patients treated in either the EMBRACE
trial or the preceding phase II studies reported outcomes
according to age. A total of 10% of patients who were
included in these studies were aged ≥70 years. No signifi-
cant differences were observed in ORR, PFS, or OS by
age. Toxicity was similar across all age groups, although
the incidence of grade 3 and 4 fatigue and peripheral
neuropathy was highest in patients aged ≥70 years [14, 21].
Elderly patients with good ECOG-Performance Status
treated with eribulin have also shown similar OS, PFS, re-
sponse rate, clinical benefit and tolerability in smaller
studies when compared to younger patients [21, 22]. In our
cohort of patients, we observed significant differences in
OS according to age, with significantly better OS and PFS
in patients ≥70 years of age compared to those younger.
Similar ORR but with a distinct pattern regarding PR or SD
and tolerability were observed in patients in both age
groups.
The role of BMI and comorbidities in the outcomes of
patients treated with eribulin is still a matter of debate.
In some historical series, patients who are overweight
and obese have shown worse outcomes compared to the
normal weight group [20, 23, 24]. In an Italian observa-
tional multicentric study, there was a significantly better
PFS in the lowest category of BMI, but no differences in
OS were observed [25]. In our cohort, no differences in
OS were found amongst patients with normal weight
compared to overweight and obese patients or those
with and without comorbidities.
In our study, 21% of patients had CNS involvement,
which is often an exclusion criterion in most clinical tri-
als, unless patients are previously treated with local ther-
apy. Of those patients, 25% achieved SD and 20%
achieved PR, which supports the efficacy of eribulin in
patients with CNS involvement. The efficacy in patients
with CNS disease was not related to previous treatment
with whole brain radiotherapy. The rationale for poten-
tial positive effect of eribulin on brain metastases is not
clear. Preclinical evidence suggests that the agent does
not cross the blood–brain barrier (BBB) to a significant
extent [15, 26]. Radiation therapy can compromise the
BBB, which may help drugs enter into the brain [27].
However, this BBB drug crossing can be also explained by
the altered BBB due to the presence of brain metastases
alone. In the 301 study, a lower proportion of patients in
the eribulin arm developed CNS metastases compared to
the capecitabine arm (2.4% vs 4.6%, respectively) [7].
Moreover, in the three patients with known stable brain
metastases included in that trial and treated with eribulin,
a reduction in the size of brain lesions was also observed.
Some case reports have also shown efficacy with eribulin
at the CNS level, both in patients previously treated with
radiotherapy and not [28, 29].
The pattern of disease progression in patients treated
with eribulin is distinctive. Most patients in our series
progressed in pre-existing M1 sites (75%). This fact may
Table 3 Most common adverse events following the Common Terminology Criteria for Adverse Events (CTCAE 3.0)
Grades Neurotoxicity Alopecia Asthenia Thrombocytopenia Anaemia Neutropenia Oral Mucositis Hepatotoxicity
1 17 (18.5%) 13 (14.1%) 36 (39.1%) 5 (5.4%) 17 (18.5%) 4 (4.3%) 10 (10.9%) 15 (16.3%)
2 18 (19.6%) 11 (12%) 37 (40.2%) 2 (2.2%) 6 (6.5%) 6 (6.5%) 3 (3.3%) 2 (2.2%)
3 7 (7.6%) – 9 (9.8%) 1 (1.1%) 0 9 (9.8%) 1 (1.1%) 2 (2.2%)
4 0 – 0 0 0 10 (10.9%) a 0 0
a Nine out of ten had febrile neutropenia
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reflect the inhibitory effect of eribulin in the EMT, redu-
cing cancer cell migration and invasiveness; however, we
did not find any information about the pattern of pro-
gression in patients who received other oncospecific
treatments [1–3]. It has been previously reported that
patients with ABC who develop tumour progression
with new metastases have worse outcomes compared to
those patients whose disease progresses due to growth
of pre-existing lesions [11, 30].
Regarding toxicity, most patients in our series demon-
strated acceptable tolerability of the eribulin treatment.
The most frequent grade 3/4 toxicities were asthenia,
neurotoxicity and neutropenia and were manageable. Re-
markably, the proportion of grade 3 neutropenia was
lower in our study than in pivotal trials (9.8% vs 23.4%), as
well as grade 4 toxicities with 10.2% in our study (all of
them neutropenia) versus 27.7% in the pooled analysis [8].
This study has several strengths and limitations. Our
study reflects the everyday clinical practice use of eribulin
and analyzes multiple variables such as BMI, age > 70
years and activity in patients with CNS metastases that
have not been previously addressed and studied together
in patients outside of a clinical trial. The major limitations
of this study are the limited number of patients included
and its retrospective nature without having a dedicated
pre-planned design of patient management and data col-
lection, which can lead to potential biases. It is worth not-
ing that, during the study period, several clinical trials
evaluating new targeted drugs in combination with eribu-
lin were ongoing and those patients were not included in
this study.
Conclusion
The efficacy of eribulin in terms of OS and PFS observed in
our study is similar to that reported in pivotal clinical trials.
However, clinical benefit and ORR were higher, and signifi-
cantly longer survival was seen in patients with HR-positive
tumors, low burden disease and older than 70 years of age.
Remarkably, less toxicity was found compared to previous
studies and relevant CNS efficacy was observed. Despite the
potential biases of this study, its results might be useful in
clinical practice due to the limited existing data of eribulin’s
efficacy and safety focused on age, BMI and CSN.
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